Development of novel cancer chemopreventive agents in Europe - Neglected Cinderella or rising phoenix?. A critical commentary. ESF Workshop on Cancer Chemoprevention, DKFZ, Heidelberg, September 18-20, 2005

European Journal of Cancer

Volumn 42, Issue 10, 2006, Pages 1338-1343

  Gerhauser, Clarissa ^a   Bartsch, Helmut ^a   Crowell, James ^b   Flora, Silvio De ^c   D'Incalci, Maurizio ^d   Dittrich, Christian ^e   Frank, Norbert ^a   Mihich, Enrico ^f   Steffen, Christian ^g   Tortora, Giampaolo ^h   Gescher, Andreas ⁱ  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF GENOA   (Italy)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e Applied Cancer Research Institute for Translational Research Vienna   (Austria)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g Federal Institute for Drugs and Medical Devices Bundesinstitut für Arzneimittel und Medizinprodukte   (Germany)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁱ UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Biomarkers; Cancer chemoprevention; Chemopreventive agents; Clinical studies; Commentary; Europe; European Science Foundation (ESF) Workshop; Experimental animal models; Pharmaceutical industry; RAPID program

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ASCORBIC ACID; BETA CAROTENE; BIOLOGICAL MARKER; CELECOXIB; CURCUMIN; CYCLIN DEPENDENT KINASE INHIBITOR; EPIGALLOCATECHIN GALLATE; FENRETINIDE; FLAVONE; FLAVONOID; GEFITINIB; GLUCOSINOLATE; ISOTHIOCYANIC ACID; LYCOPENE; MACROGOL; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR ANTIBODY; SELENIUM; TAMOXIFEN; TERPENE; XANTHOHUMOL;

ABSENCE OF SIDE EFFECTS; ARTICLE; CANCER; CANCER PREVENTION; CANCER RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG INTOXICATION; DRUG SAFETY; EUROPE; EXPERIMENTAL MODEL; GERMANY; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CHEMOPREVENTION; CONGRESSES; DRUG DESIGN; HUMANS; NEOPLASMS;

EID: 33745250518     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.02.007     Document Type: Article

References (43)

1. Rembrink K., Romijn J.C., van der Kwast T.H., et al. Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate 31 (1997) 168-174
2. Schroder F.H., Kranse R., Barbet N., et al. Prostate-specific antigen: A surrogate endpoint for screening new agents against prostate cancer?. Prostate 42 (2000) 107-115
3. De Flora S., D'Agostini F., Balansky R.M., et al. Modulation of cigarette smoke-related end-points in mutagenesis and carcinogenesis. Mutat Res 523-524 (2003) 237-252
4. Izzotti A., Bagnasco M., Cartiglia C., et al. Chemoprevention of genome, transcriptome, and proteome alterations induced by cigarette smoke in rat lung. Eur J Cancer 41 (2005) 1864-1874
5. Corpet D.E., and Pierre F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur J Cancer 41 (2005) 1911-1922
6. Maddison K., and Clarke A.R. New approaches for modelling cancer mechanisms in the mouse. J Pathol 205 (2005) 181-193
7. Gerhauser C., Alt A., Heiss E., et al. Cancer chemopreventive activity of Xanthohumol, a natural product derived from hop. Mol Cancer Ther 1 (2002) 959-969
8. Gerhauser C. Beer constituents as potential cancer chemopreventive agents. Eur J Cancer 41 (2005) 1941-1954
9. Cai H, Al-Fayez M, Tunstall R, et al. The rice bran constituent tricin potently inhibits cyclooxygenase enzymes and interfers with intestinal carcinogenesis in ApcMin mice. Mol. Cancer Ther, in press.
10. Owen R.W., Haubner R., Wurtele G., et al. Olives and olive oil in cancer prevention. Eur J Cancer Prev 13 (2004) 319-326
11. Owen R.W., Mier W., Giacosa A., et al. Phenolic compounds and squalene in olive oils: the concentration and antioxidant potential of total phenols, simple phenols, secoiridoids, lignansand squalene. Food Chem Toxicol 38 (2000) 647-659
12. Beauchamp G.K., Keast R.S., Morel D., et al. Phytochemistry: ibuprofen-like activity in extra-virgin olive oil. Nature 437 (2005) 45-46
13. Etminan M., Takkouche B., and Caamano-Isorna F. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev 13 (2004) 340-345
14. Stahl W., and Sies H. Antioxidant activity of carotenoids. Mol Aspects Med 24 (2003) 345-351
15. Smith T.K., Lund E.K., Clarke R.G., et al. Effects of Brussels sprout juice on the cell cycle and adhesion of human colorectal carcinoma cells (HT29) in vitro. J Agric Food Chem 53 (2005) 3895-3901
16. Brennan P., Hsu C.C., Moullan N., et al. Effect of cruciferous vegetables on lung cancer in patients stratified by genetic status: a mendelian randomisation approach. Lancet 366 (2005) 1558-1560
17. Mithen R., Faulkner K., Magrath R., et al. Development of isothiocyanate-enriched broccoli, and its enhanced ability to induce phase 2 detoxification enzymes in mammalian cells. Theor Appl Genet 106 (2003) 727-734
18. van Breda S.G., van Agen E., Engels L.G., et al. Altered vegetable intake affects pivotal carcinogenesis pathways in colon mucosa from adenoma patients and controls. Carcinogenesis 25 (2004) 2207-2216
19. van Breda S.G., van Agen E., van Sanden S., et al. Vegetables affect the expression of genes involved in anticarcinogenic processes in the colonic mucosa of C57BL/6 female mice. J Nutr 135 (2005) 1879-1888
20. Corpet D.E., Parnaud G., Delverdier M., et al. Consistent and fast inhibition of colon carcinogenesis by polyethylene glycol in mice and rats given various carcinogens. Cancer Research 60 (2000) 3160-3164
21. Tosetti F., Ferrari N., De Flora S., et al. "Angioprevention": Angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 16 (2002) 2-14
22. Pfeffer U., Ferrari N., Dell'eva R., et al. Molecular mechanisms of action of angiopreventive anti-oxidants on endothelial cells: Microarray gene expression analyses. Mutat Res 591 (2005) 198-211
23. De Flora S., and Ferguson L.R. Overview of mechanisms of cancer chemopreventive agents. Mutat Res 591 (2005) 8-15
24. Gasco M., Argusti A., Bonanni B., et al. SERMs in chemoprevention of breast cancer. Eur J Cancer 41 (2005) 1980-1989
25. Petty W.J., Li N., Biddle A., et al. A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis. J Natl Cancer Inst 97 (2005) 1645-1651
26. van Zandwijk N. Chemoprevention in lung carcinogenesis-an overview. Eur J Cancer 41 (2005) 1990-2002
27. Schroder F.H., Roobol M.J., Boeve E.R., et al. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol 48 (2005) 922-930
28. Kronborg O. Colon polyps and cancer. Endoscopy 36 (2004) 3-7
29. Sharma R.A., Euden S.A., Platton S.L., et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10 (2004) 6847-6854
30. Sharma R.A., Gescher A.J., and Steward W.P. Curcumin: The story so far. Eur J Cancer 41 (2005) 1955-1968
31. Garcea G., Berry D.P., Jones D.J., et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14 (2005) 120-125
32. Bremmer J.F., Braakhuis B.J., Ruijter-Schippers H.J., et al. A noninvasive genetic screening test to detect oral preneoplastic lesions. Lab Invest 85 (2005) 1481-1488
33. Fayette J., and Soria J.C. [Targeted molecular therapy: the example of Iressa (ZD1839)]. Med Sci (Paris) 19 (2003) 1052-1054
34. Zuluaga A.F., Follen M., Boiko I., et al. Optical coherence tomography: A pilot study of a new imaging technique for noninvasive examination of cervical tissue. Am J Obstet Gynecol 193 (2005) 83-88
35. Carlson K., Pavlova I., Collier T., et al. Confocal microscopy: Imaging cervical precancerous lesions. Gynecol Oncol 99 3 Suppl 1 (2005) S84-S88
36. Nida D.L., Rahman M.S., Carlson K.D., et al. Fluorescent nanocrystals for use in early cervical cancer detection. Gynecol Oncol 99 3 Suppl 1 (2005) S89-S94
37. Howell A., Sims A.H., Ong K.R., et al. Mechanisms of Disease: prediction and prevention of breast cancer-cellular and molecular interactions. Nat Clin Pract Oncol 2 (2005) 635-646
38. Fabian C.J., Kimler B.F., Mayo M.S., et al. Breast-tissue sampling for risk assessment and prevention. Endocr Relat Cancer 12 (2005) 185-213
39. Celis J.E., Gromov P., Gromova I., et al. Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research. Mol Cell Proteomics 2 (2003) 369-377
40. Blackledge G.R. The difficulties industry is facing with investigators. Eur J Cancer 41 (2005) 2210-2212
41. Clark R.F., Strukle E., Williams S.R., et al. Selenium poisoning from a nutritional supplement. JAMA 275 (1996) 1087-1088
42. Thiery-Vuillemin A., Nguyen T., Pivot X., et al. Molecularly targeted agents: their promise as cancer chemopreventive interventions. Eur J Cancer 41 (2005) 2003-2015
43. Crowell J.A. The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: an overview. Eur J Cancer 41 (2005) 1889-1910